Clinical Research
News & Careers
Search the Site
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile


Vertex Pharmaceuticals Incorporated 

130 Waverly Street

Cambridge  Massachusetts  02139-4242  U.S.A.
Phone: 617-444-6100 Fax: 617-444-6680


The Science of Possibility.

The first thing you’ll notice about Vertex is that we are not a conventional pharmaceutical company. Each and every person at Vertex is driven by a passion for fearless innovation and a bold desire to transform the lives of millions with new medicines. Together, by creating new possibilities in medicine, our employees are quite literally changing the world.

Vertex scientists and our collaborators are working on new medicines to advance the treatment of hepatitis C, cystic fibrosis, rheumatoid arthritis and other life-threatening diseases. Our development pipeline includes several investigational drugs that have the potential to transform the treatment of serious diseases. Every day brings us a step closer to getting patients the medicines they need and potentially changing their lives in previously unimaginable ways. It’s a demanding yet incredibly rewarding experience that cannot help but change your life in the process, too.

We employ more than 2,000 of the industry’s best and brightest people at locations around the world – all of us working toward tomorrow’s breakthrough medicines.

For more information on Vertex, please visit For information on career opportunities with Vertex, please visit

Key Contacts:
Patient Inquiries:

This div will be replaced

 Key Statistics

Ownership: Public

Web Site: Vertex Pharmaceuticals (MA)
Employees: ~1000
Symbol: VRTX


Cystic Fibrosis Foundation Therapeutics, Inc.  (VX-770 for CF)

Kissei Pharmaceutical Co., Ltd.  (VX-702 for RA)

GlaxoSmithKline  (VX-409 and Backup Compounds)

Janssen Pharmaceutica N.V.  (telaprevir for HCV) - Europe, South America, Australia, the Middle East and other countries

Merck & Co.  (MK-0457 (VX-680), MK-6592 (VX-667) and VX-689 for Cancer)

Mitsubishi Pharma Corporation  (telaprevir for HCV) - Japan and certain Far East countries

 Company News
Tiny Startup Spyryx Looks to One-Up Vertex Pharmaceuticals (MA) (VRTX) With One-Size-Fits-All Cystic Fibrosis Therapy 2/13/2015 7:15:29 AM
Vertex Pharmaceuticals (MA) (VRTX) Learns From Gilead Sciences, Inc. (GILD)'s Solvadi Mistakes as it Preps for CF Drug Launch 2/2/2015 6:52:21 AM
Vertex Pharmaceuticals (MA) (VRTX)'s CEO Believes Obama's $215 Million Plan Would Mean Better New Drugs 2/2/2015 6:44:01 AM
Vertex Pharmaceuticals (MA) (VRTX)'s R&D Chief to Meet With Obama Today 1/30/2015 6:21:57 AM
Vertex Pharmaceuticals (MA) (VRTX) Release: FDA Approves KALYDECO® (Ivacaftor) For Use In People With Cystic Fibrosis Ages 6 And Older Who Have The R117H Mutation 12/30/2014 8:30:10 AM
Renowned Geneticist Altshuler Ditches The Broad Institute For Vertex Pharmaceuticals (MA) (VRTX) 12/15/2014 8:44:06 AM
Vertex Pharmaceuticals (MA) (VRTX) To Present At Deutsche Bank (DB) BioFEST On December 2 11/21/2014 12:37:31 PM
Biotech Investors Bullish On Large Cap; Citi Adds Vertex Pharmaceuticals (MA) (VRTX), BioMarin Pharmaceutical Inc. (BMRN) and Tesaro, Inc. (TSRO) To Most Preferred 11/14/2014 3:27:58 PM
Vertex Pharmaceuticals (MA) (VRTX) Submits Applications In The U.S. And Europe For Approval Of Lumacaftor In Combination With Ivacaftor For People With Cystic Fibrosis Who Have Two Copies Of The F508del Mutation 11/5/2014 10:31:25 AM
Vertex Pharmaceuticals (MA) (VRTX) Surges As FDA Advisory Panel Approves Kalydeco's Label Expansion 10/22/2014 5:35:50 AM